Back to Clinical Trials
N/ARecruiting

Zesty Exercise System for Therapeutic Engagement

Sponsored by Emory University

About this study

This study will evaluate exercise delivered through the Zesty Exercise System for Therapeutic Engagement (ZEST-E) for people with Parkinson's disease when sessions are monitored either in person or remotely. Participants will complete robot-guided exercise three times per week for three weeks. The study will assess feasibility, retention, safety, acceptability, and tolerability of remotely monitored ZEST-E and will measure changes in functional performance using the Standing Forward Reach test and the 30-Second Chair Stand test. These outcomes reflect range of motion and lower-body strength targeted by the exercise program.

Parkinson's disease is associated with reduced range of motion, impaired postural control, and decreased lower-body strength, which contribute to mobility limitations and reduced functional independence. Exercise is an essential component of symptom management and has been shown to improve strength, balance, and overall physical function. Many individuals with Parkinson's disease, however, face barriers to accessing supervised exercise, including transportation challenges, limited availability of trained providers, and difficulty maintaining consistent participation. Remote delivery of structured exercise may increase accessibility, but its feasibility and safety for use with robotic exercise systems have not been fully evaluated. The Zesty Exercise System for Therapeutic Engagement (ZEST…

Where this study is enrolling

  • Emory University, 57 Executive Park S NE, Ste 200

    Atlanta, Georgia

    I'm interested
Who can participate

Inclusion criteria

  • ✓Older adults with mild to moderate PD.

Exclusion criteria

  • ✕Acute medical illness requiring hospitalization;
  • ✕Under 40 years old;
  • ✕Uncontrolled congestive heart failure;
  • ✕History of stroke in the past three years;
  • ✕Inability to perform study procedures;
  • ✕Medical or physical conditions that would preclude participation (e.g., severe arthritis or mobility problems, uncontrolled hypertension or diabetes, renal failure, history of angina with activity);
  • ✕On medications that could adversely affect cognition, e.g.: antipsychotics, opioids, stimulants, chemotherapy;
  • ✕Psychotic disorders;
  • ✕Confounding neurologic conditions (e.g., active central nervous system opportunistic infections, seizure disorders, head injury with loss of consciousness \>30 minutes, intracranial neoplasms, stroke with neurological or neuropsychiatric sequelae);
  • ✕Substance Use Disorder, Major Depressive and Generalized Anxiety Disorders within six months of evaluation;
  • ✕Hohn \& Yahr \> 3
  • ✕MoCA \<17

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.